{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"255"}],"title":"NAb Negative"},{"measurements":[{"groupId":"OG000","value":"0"}],"title":"NAb Positive"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"255"}],"units":"Participants"}],"description":"The NAb status of each participant was categorized as follows:\n\n* Negative - Samples that tested negative in the ADA assay, or samples positive in the ADA assay but tested negative in the NAb assay\n* Positive","groups":[{"description":"Participants received cemiplimab monotherapy","id":"OG000","title":"Cemiplimab"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The NAb analysis set included all treated participants from the AAS who received any amount of study drug, with at least one non-missing NAb result (either assigned or assessed) following the first dose of study drug.","reportingStatus":"POSTED","timeFrame":"Up to 73.5 months","title":"Number of Participants With Neutralizing Antibodies (NAb)","type":"SECONDARY","unitOfMeasure":"Participants"}